


PHARMACEUTICAL 2023

Xilio Therapeutics Inc. Rank 198 of 446







PHARMACEUTICAL 2023

Xilio Therapeutics Inc. Rank 198 of 446



The relative strengths and weaknesses of Xilio Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xilio Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Xilio Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 108%, being 65% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	124,496
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,119
Liabilities, Non-Current	9,234
Other Assets	7,414
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	3,165
Other Net Income	927
Other Revenues	0
Property and Equipment	7,255
Research and Development	59,201
Selling, General and Administrative Expense	29,948

Output Variable	Value in 1000 USD
Assets	139,165
Liabilities	33,518
Expenses	89,149
Revenues	0
Stockholders Equity	105,647
Net Income	-88,222
Comprehensive Net Income	-88,222
Economic Capital Ratio	108%

